Table 1. Clinicopathological and treatment characteristics of females with mTNBC.
| Characteristics | No. of females (n = 118) | Percentage (%) |
|---|---|---|
| Group age in years | ||
| ≤40 | 32 | 27.1 |
| 41–59 | 56 | 47.5 |
| ≥60 | 30 | 25.4 |
| Menopausal status | ||
| Premenopausal | 43 | 36.4 |
| Postmenopausal | 72 | 61.0 |
| Missing | 3 | 2.5 |
| hCCIa | ||
| Score 6 | 91 | 77.1 |
| Score ≥7 | 27 | 22.9 |
| Clinical tumor size | ||
| T0 | 3 | 2.5 |
| T2 | 13 | 11.0 |
| T3 | 14 | 11.9 |
| T4 | 85 | 72.0 |
| Missing | 3 | 2.5 |
| Clinical lymph node status | ||
| N0 | 14 | 11.9 |
| N1 | 48 | 40.7 |
| N2 | 25 | 21.2 |
| N3 | 27 | 22.9 |
| Missing | 4 | 3.4 |
| Histologic grade | ||
| Grade II | 11 | 9.3 |
| Grade III | 71 | 60.2 |
| Missing | 36 | 30.5 |
| Site of metastases | ||
| 1 organ | 58 | 49.2 |
| 2 organs | 36 | 30.5 |
| 3 organs | 14 | 11.9 |
| 4 organs | 9 | 7.6 |
| 5 organs | 1 | 0.8 |
| Chemotherapy | 77 | 65.3 |
ahCCI, hypertension-augmented Charlson comorbidity index